Absci (ABSI) Share-based Compensation (2020 - 2026)
Absci (ABSI) posted Share-based Compensation of $4.4 million for Q1 2026, up 2.89% sequentially from $4.3 million in Q4 2025, and down 10.85% YoY from $4.9 million in Q1 2025.
Analysis
Absci (ABSI) Share-based Compensation (2020 - 2026) Analysis & Trends
Absci has reported Share-based Compensation for 7 years, with the latest figure at $4.4 million in Q1 2026.
- Quarterly Share-based Compensation fell 10.85% year-over-year to $4.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $17.8 million (down 14.38% YoY) and the FY2025 annual result came in at $18.3 million, down 5.81% from the prior year.
- Share-based Compensation rose to $4.4 million in Q1 2026 per ABSI's latest filing, from $4.3 million in the prior quarter.
- Over five years, Share-based Compensation peaked at $19.0 million in Q4 2024 and troughed at -$11.4 million in Q4 2022.
- A 5-year average of $3.4 million and a median of $4.2 million in 2022 frame the typical range for Share-based Compensation.
- The widest YoY moves for Share-based Compensation: up 1500.38% in 2022, down 452.88% in 2022.
- Over 5 years, Share-based Compensation stood at -$11.4 million in 2022, then surged by 200.1% to $11.4 million in 2023, then soared by 66.6% to $19.0 million in 2024, then plunged by 77.62% to $4.3 million in 2025, then rose by 2.89% to $4.4 million in 2026.
- According to Business Quant data, Share-based Compensation over the past three periods registered $4.4 million, $4.3 million, and $4.4 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Share-based Compensation (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 108.10 Mn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 243.00 Mn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | 120.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | 277.20 Mn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 137.41 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 86.63 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 41.25 Mn |
| 10 | Absci | 1.39 Bn | 1.19 Bn | - | 5.24 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 5.24 Mn |
| Mar 31, 2026 | 4.38 Mn |
| Dec 31, 2025 | 4.26 Mn |
| Sep 30, 2025 | 4.40 Mn |
| Jun 30, 2025 | 4.75 Mn |
| Mar 31, 2025 | 4.91 Mn |
| Dec 31, 2024 | 5.07 Mn |
| Sep 30, 2024 | 5.51 Mn |
| Jun 30, 2024 | 5.29 Mn |
| Mar 31, 2024 | 3.59 Mn |
| Dec 31, 2023 | 3.18 Mn |
| Sep 30, 2023 | 2.54 Mn |
| Jun 30, 2023 | 3.04 Mn |
| Mar 31, 2023 | 2.65 Mn |
| Dec 31, 2022 | 1.02 Mn |
| Sep 30, 2022 | 3.57 Mn |
| Jun 30, 2022 | 4.21 Mn |
| Mar 31, 2022 | 3.74 Mn |
| Dec 31, 2021 | 3.23 Mn |
| Sep 30, 2021 | 3.78 Mn |